Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Photodynamic therapy for bilateral and simultaneous choroidal neovascularization in stargardt disease.

Authors:
Ricardo Miguel Japiassú Oswaldo Ferreira Moura Brasil Hugo Soares Maia André Soares Maia Oswaldo Moura Brasil

Retin Cases Brief Rep 2008 ;2(1):9-11

From Instituto Brasileiro de Oftalmologia, Rio de Janeiro, Brazil.

Background: Stargardt disease may lead to chronic destructive changes to the retinal pigment epithelium and secondarily cause a lesion in the Bruch membrane, predisposing to subsequent subretinal choroidal neovascularization (CNV).

Methods: The authors report an angiographically documented, bilateral, and simultaneous case of CNV in Stargardt disease that was successfully treated with photodynamic therapy (PDT).

Results: A 53-year-old man with unequivocal Stargardt disease presented with CNV in both eyes simultaneously. Best-corrected visual acuity was 20/30 in the right eye and 20/40 in the left eye. PDT was performed in both eyes and vision improved to 20/25 in the right eye and 20/30 in the left eye. The lesions recurred 3 months later when vision had decreased to 20/40 in the right eye and 20/60 in the left eye. Retreatment with PDT was performed in both eyes and vision improved to 20/30 in the right eye and 20/50 in the left eye. No further recurrence was observed for 4 months.

Conclusion: Considering the positive short-term outcome in this case as well as the limited data available, PDT may be considered in cases of CNV in Stargardt disease.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICB.0b013e3180467837DOI Listing
November 2014

Publication Analysis

Top Keywords

stargardt disease
20
left eye
16
vision improved
8
choroidal neovascularization
8
eyes vision
8
performed eyes
8
pdt performed
8
bilateral simultaneous
8
photodynamic therapy
8
20/30 eye
8
eye
8
cnv stargardt
8
stargardt
5
disease
5
left
4
eye 20/30
4
20/30 left
4
20/40 left
4
20/25 eye
4
eye 20/40
4

Similar Publications

The Direct Healthcare Cost of Stargardt Disease: A Claims-Based Analysis.

Authors:
Kanza Aziz Bonnielin K Swenor Joseph K Canner Mandeep S Singh

Ophthalmic Epidemiol 2021 Feb 21:1-7. Epub 2021 Feb 21.

Wilmer Eye Institute, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.

: Stargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail, so we aimed to estimate the direct healthcare cost of SD. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Nanocarriers, Progenitor Cells, Combinational Approaches, and New Insights on the Retinal Therapy.

Authors:
Elham Pishavar Hongrong Luo Johanna Bolander Antony Atala Seeram Ramakrishna

Int J Mol Sci 2021 Feb 10;22(4). Epub 2021 Feb 10.

Center for Nanofibers and Nanotechnology, National University of Singapore, Singapore 117581, Singapore.

Progenitor cells derived from the retinal pigment epithelium (RPECs) have shown promise as therapeutic approaches to degenerative retinal disorders including diabetic retinopathy, age-related macular degeneration and Stargardt disease. However, the degeneration of Bruch's membrane (BM), the natural substrate for the RPE, has been identified as one of the major limitations for utilizing RPECs. This degeneration leads to decreased support, survival and integration of the transplanted RPECs. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Clinical and electroretinographic profile of 27 patients with Stargardt disease treated at a hospital in Brazil.

Authors:
Letícia Schemberger Schafranski Izabelle Yumi Honda Müller Mario Teruo Sato

Arq Bras Oftalmol 2021 Feb 3. Epub 2021 Feb 3.

Sector of Neuro-Ophthalmology and Ocular Electrophysiology of the Complexo Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brazil.

Purpose: Stargardt disease is the most common type of juvenile-onset macular dystrophy. It is bilateral and symmetrical in appearance, affects the macula, and its main characteristic is the loss of central vision that starts in the first or second decade of life. The purpose of this study was to describe the profile of the patients evaluated at the Complexo Hospital de Clínicas da Universidade Federal do Paraná, as well as describe the electroretinographic findings with the full-field electroretinogram in these patients. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease.

Authors:
Jeffrey N Weiss Steven Levy

Medicines (Basel) 2021 Feb 3;8(2). Epub 2021 Feb 3.

MD Stem Cells, 3 Sylvan Road South, Westport, CT 06880, USA.

Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Stargardt Disease: a clinical case report of two sisters with different clinical development.

Authors:
S Peñarrocha-Oltra Á Rallo-López E Escrivá-Pastor

Arch Soc Esp Oftalmol 2021 Feb 1. Epub 2021 Feb 1.

Hospital Lluis Alcanyis, Xàtiva, Valencia, España.

The purpose of this article is to describe the clinical manifestations and complementary diagnostic tests of two sisters aged 26 and 31 with a diagnosis of Stargardt's disease. One of them presented with an initial visual acuity of 0.7 and showed a progressive central visual loss due to the atrophy of the external layers of the retina in the subfoveal region. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap